Interview with Marco Cartolari, CEO, Scharper
Scharper’s history in the Italian market begins in 1958, but the company as we see it today was really created in the mid nineties, when you founded La Farmochimica Italiana…
Address: Viale Ortles, 12 – 20139 Milan (MI),Italy
Tel: +39.02.2629161
Web: http://www.scharper.it/introscharper.htm
Created in 1995 by Dr. Lino Cartolari as La Farmochimica Italiana Srl (LFI), the company then purchased Scharper trademark in 1996 and signs several licensing agreements with different pharma leaders.
Scharper now operates in selected therapeutic areas, and focuses on high profile prescription drugs
(primarily through in-licensing arrangements) as well as highly researched and clinically supported medical foods, nutraceuticals, cosmeceuticals and medical devices( to date developed primarily internally).
Scharper’s focus is unique in that it treats non-drug products with the same scientific scrutiny and rigour as drug products.
Scharper’s history in the Italian market begins in 1958, but the company as we see it today was really created in the mid nineties, when you founded La Farmochimica Italiana…
You declared in a recent interview that Zambon Group will always keep complying with the vision of your father Alberto, who has always refused acquisition offers from multinationals- a striking…
You are specialised in Cardiology at Padua University, in Tropical Medicine and Hygiene at London University and in Pharmacology at Modena University, in Communication at Bocconi University in Milan, and…
Ferlito Farmaceutici was established in 1937 and has since then grown to become one of the most renowned pharmaceutical pre-wholesalers in Italy. Which specific values of Ferlito do you think…
Recordati was created in 1926, and the combined work of three generations turned the small laboratory not only into a local success story but also a broad European Group. Your…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
Since 1982, CNR has been the Italian public body which most contributed to the creation of inventions and innovations. What have been the main strategies behind such a success in…
Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and…
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
When you were appointed General Director of the Agenzia Italiana del Farmaco (AIFA) in 2007, the dedicated Investigation Commission highlighted the need for an in-depth reorganization of the Agency in…
When you became President of Sankyo Pharma Italy in 2003 one of your objectives was to maximize sales of the existing portfolio- and the company’s sales have impressively tripled in…
Intermediate distribution plays a crucial role in establishing bridges between industrial production and final delivery to patients- and in Italy, this function is executed with highly contained costs and commercial…
You have led a successful career within the Solvay Group in various European countries. Looking back at all these international assignments, including you current function of regional Director South Europe,…
See our Cookie Privacy Policy Here
